Municipal Employees Retirement System of Michigan bought a new position in shares of LeMaitre Vascular Inc (NASDAQ:LMAT) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 4,490 shares of the medical instruments supplier’s stock, valued at approximately $106,000.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. BlackRock Inc. increased its stake in LeMaitre Vascular by 2.2% in the fourth quarter. BlackRock Inc. now owns 2,601,309 shares of the medical instruments supplier’s stock valued at $61,496,000 after purchasing an additional 56,161 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of LeMaitre Vascular by 35.4% in the third quarter. JPMorgan Chase & Co. now owns 15,376 shares of the medical instruments supplier’s stock worth $595,000 after buying an additional 4,020 shares during the period. MetLife Investment Advisors LLC boosted its position in shares of LeMaitre Vascular by 58.0% in the third quarter. MetLife Investment Advisors LLC now owns 12,092 shares of the medical instruments supplier’s stock worth $468,000 after buying an additional 4,441 shares during the period. Legal & General Group Plc boosted its position in shares of LeMaitre Vascular by 11.0% in the third quarter. Legal & General Group Plc now owns 33,785 shares of the medical instruments supplier’s stock worth $1,295,000 after buying an additional 3,360 shares during the period. Finally, Bank of Montreal Can boosted its position in shares of LeMaitre Vascular by 99.1% in the fourth quarter. Bank of Montreal Can now owns 1,113 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 554 shares during the period. Institutional investors own 77.19% of the company’s stock.
A number of research analysts recently commented on LMAT shares. Zacks Investment Research downgraded LeMaitre Vascular from a “hold” rating to a “sell” rating in a report on Thursday, February 7th. Lake Street Capital restated a “hold” rating and set a $24.00 price objective on shares of LeMaitre Vascular in a research note on Wednesday, January 23rd. Roth Capital restated a “neutral” rating on shares of LeMaitre Vascular in a research note on Thursday, February 21st. ValuEngine upgraded LeMaitre Vascular from a “sell” rating to a “hold” rating in a research note on Wednesday, February 20th. Finally, BidaskClub upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Friday, March 1st. Six research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $31.00.
LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Wednesday, May 1st. The medical instruments supplier reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.02). The firm had revenue of $28.48 million for the quarter, compared to the consensus estimate of $27.94 million. LeMaitre Vascular had a net margin of 20.92% and a return on equity of 16.76%. The business’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.19 earnings per share. As a group, equities analysts predict that LeMaitre Vascular Inc will post 0.83 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 6th. Stockholders of record on Wednesday, May 22nd will be paid a dividend of $0.085 per share. This represents a $0.34 annualized dividend and a dividend yield of 1.20%. The ex-dividend date is Tuesday, May 21st. LeMaitre Vascular’s dividend payout ratio is presently 40.48%.
In other news, insider Trent G. Kamke sold 16,604 shares of the firm’s stock in a transaction on Friday, February 22nd. The stock was sold at an average price of $29.63, for a total transaction of $491,976.52. Following the completion of the sale, the insider now directly owns 19,857 shares of the company’s stock, valued at approximately $588,362.91. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 19.60% of the company’s stock.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.
Featured Article: Current Ratio
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.